The Worlds #1 Renewable Energy Network for News & Information
Sign In
or
Register
Sections
Home
Solar
Wind
Geothermal
Bio
Hydro
Careers
Companies
Webcasts
White Papers
Magazines
Awards
Account
Sign In
Register
Search
REW 40 Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Celgene Corp
(NQ:
CELG
)
116.89
USD
-3.35 (-2.79%)
Official Closing Price
/ Updated:
4:00 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Celgene Corp
< Previous
1
2
3
4
5
6
7
8
9
...
85
86
Next >
bluebird bio (BLUE) IPO Opens Sharply Higher
June 19, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8431091 for the full story.
Read More
from
StreetInsider.com News Articles
MannKind Corp. (NASDAQ:MNKD) and Celgene Corporation (NASDAQ:CELG) Added to Equity Profile Report's NASDAQ Decliners Watch List.
June 18, 2013
Wilmington, DE -- (SBWIRE) -- 06/18/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding MannKind Corp. (NASDAQ:MNKD) and Celgene Corporation (NASDAQ:CELG).
Read More
from
SBWire - Latest Press Releases
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals
June 18, 2013
Editor Note: For more information about this release, please scroll to bottom
Read More
from
PR Newswire
This Week’s Seminal Event
June 17, 2013
category
Market/Outlook
,
Week/Ahead
,
Market/Outlook/2013/Q2
, and 1 more.
from
Wall Street Greek
Trade of the Day: Celgene (CELG)
June 17, 2013
Read More
category
NASDAQ:CELG
from
InvestorPlace - Latest Headlines
Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
June 17, 2013
from
Business Wire News Releases
Weekly Wrap-Up + Market Forecast + Sector Watch: SPX, Nasdaq, GLD, BTK, XLE, XLF, GS, MA, V, JPM, BAC, APA, APC, HES, OXY, CELG, ONXX, GILD, BIIB, REGN, ALXN
June 17, 2013
Last weekend, in my Market Forecast, I wrote: "For the new week, stocks may need a little pause and consolidation to start the week. There is resistance between 1650 and 1660. On the down side, we...
Read More
category
XLE
,
REGN
,
APA
, and 17 more.
from
Wang's Happy Trading
NASDAQ Decliners Watch List: Echo Therapeutics, Inc. (NASDAQ:ECTE) and Celgene Corporation (NASDAQ:CELG) Added to Growing Stock Report's NASDAQ Decliners Watch List.
June 15, 2013
New York, NY -- (SBWIRE) -- 06/15/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Echo Therapeutics, Inc. (NASDAQ:ECTE) and Celgene Corporation (NASDAQ:CELG).
Read More
from
SBWire - Latest Press Releases
Warner Chilcott plc (NASDAQ:WCRX) and Celgene Corporation (NASDAQ:CELG) Added to Equity Profile Report's NASDAQ Decliners Watch List
June 14, 2013
Wilmington, DE -- (SBWIRE) -- 06/14/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Warner Chilcott plc (NASDAQ:WCRX) and Celgene Corporation (NASDAQ:CELG).
Read More
from
SBWire - Latest Press Releases
Celgene Int'l (CELG) Apremilast Hits Primary, Secondary Endpoints in BD Phase II
June 14, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8417063 for the full story.
Read More
from
StreetInsider.com News Articles
Celgene Announces Statistical Significance for Primary, Secondary Endpoints in Phase II Trial in Patients with Behçet's Disease
June 14, 2013
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG ) today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease (BD) at...
Read More
category
Contracts
,
Benzinga
,
Guidance
, and 2 more.
from
Latest Articles from Benzinga.com
Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease
June 14, 2013
from
Business Wire News Releases
Upgrade Alert for Celgene (CELG)
June 13, 2013
from
Comtex SmarTrend® News Briefs
Stock Upgrades: Bulls Run on Adidas AG
June 13, 2013
Wall Street ratings agencies set the tone for today's stock market.
Read More
category
CELG
,
GILD
from
Minyanville Headlines
Top Stocks Upgrades/Downgrades June 13, 2013
June 13, 2013
UPGRADES Celgene (NASDAQ:CELG) upgraded to Buy from Hold at Argus – Target $140 Gilead (NASDAQ:GILD) upgraded to Buy from Hold at Argus – Target $62 Ross Stores (NASDAQ:ROST) upgraded to Buy from...
Read More
category
Latest
,
Market Today
from
Wall Street Pit
Argus Upgrades Celgene (CELG) to Buy
June 13, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8413241 for the full story.
Read More
from
StreetInsider.com News Articles
Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
June 13, 2013
from
Business Wire News Releases
Moody's Boosts Outlook on Celgene (CELG) to Stable; Affirms Ratings
June 12, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8410462 for the full story.
Read More
from
StreetInsider.com News Articles
Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)
June 12, 2013
Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB ), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares...
Read More
category
Regeneron Pharmaceuticals
,
amgen
,
Benzinga
, and 35 more.
from
Latest Articles from Benzinga.com
Notable ETF Outflow Detected - IBB, REGN, AMGN, CELG
June 12, 2013
Symbols mentioned in this story: IBB, REGN, AMGN, CELG Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These...
Read More
category
ETFs
from
ETF Channel
US STOCKS-Wall Street little changed as investors mull policy path
June 12, 2013
NEW YORK, June 12 (Reuters) - U.S. stocks were little changed in early trading on Wednesday, gaining modestly amid advances in energy and materials shares, even as investors continued to mull how soon...
Read More
category
companyNews
from
Reuters: Company News
Watch for Shares of Celgene (CELG) to Approach Resistance at $122.09
June 12, 2013
from
Comtex SmarTrend® News Briefs
StreetInsider.com Pre-Open Movers 6/12: (CTB) (CYTK) (HMA) Higher; (CLSN) (FSLR) (IEP) Lower (more...)
June 12, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8409003 for the full story.
Read More
from
StreetInsider.com News Articles
Celgene (CELG) Adds $3B to Buyback Plan
June 12, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8408531 for the full story.
Read More
from
StreetInsider.com News Articles
Celgene Announces Additional $3.0 Billion Share Repurchase Program
June 12, 2013
from
Business Wire News Releases
Celgene (CELG) Unit Reports Meaningful Improvements Observed in PALACE 1
June 12, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8408329 for the full story.
Read More
from
StreetInsider.com News Articles
Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)
June 12, 2013
from
Business Wire News Releases
J&J's Stelara effective in psoriatic arthritis trial
June 11, 2013
June 11 (Reuters) - Johnson & Johnson's Stelara produced significant improvement in signs and symptoms of psoriatic arthritis through 52 weeks of treatment in a late stage study, according to data...
Read More
category
companyNews
from
Reuters: Company News
Celgene arthritis drug maintains efficacy at 52 weeks-study
June 11, 2013
June 11 (Reuters) - Celgene Corp's experimental drug for psoriatic arthritis maintained its ability to significantly reduce painful symptoms through 52 weeks of treatment, according to data from a late...
Read More
category
companyNews
from
Reuters: Company News
NASDAQ 100's Update, In focus: WCRX, CELG, FISV, FSLR, NIHD
June 11, 2013
New York, June 11th (TradersHuddle.com) - The NASDAQ 100 Index is lower trading at 2990.49, which represents -0.01% versus its previous close. The index is under pressure with more than 60% of its...
Read More
from
TradersHuddle.com
< Previous
1
2
3
4
5
6
7
8
9
...
85
86
Next >
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here